- A new once-daily pill, baxdrostat, developed by AstraZeneca, has demonstrated significant reductions in blood pressure for patients, including those already on other medications.
- Experts estimate this drug could potentially assist up to 10 million people in the UK and half a billion worldwide who suffer from high blood pressure.
- Baxdrostat functions by blocking an enzyme responsible for producing aldosterone, a hormone vital for regulating blood pressure and the body's salt content.
- Results from the global BaxHTN trial, involving nearly 800 patients, showed an average blood pressure reduction of 9-10 mmHg after 12 weeks, which is significant enough to lower the risk of heart problems.
- Around four in 10 patients receiving baxdrostat achieved healthy blood pressure levels, compared to fewer than two in 10 in the placebo group, with AstraZeneca aiming to file for regulatory approval this year.
IN FULL
